Hepatitis C Treatment and Behavioral Risk Among Men Who Have Sex With Men With HIV: Comparing Interferon and Direct-Acting Antiviral Eras
MSM treated with DAAs, compared with MSM treated with IFN, had higher levels of HCV-related risk behavior during treatment. The higher risk of HCV reinfection in the DAA-era underscores the need for ongoing HCV testing and behavioral interventions against HCV.
Authors
- R. R. Bart (ORCID: https://orcid.org/0000-0002-7235-8007)
- Peter Santa Maria
- Janke Schinkel (ORCID: https://orcid.org/0000-0002-1112-0644)
- M. Gancarz-Kausch Amy
- Bronwen Anders
- Kees Brinkman (ORCID: https://orcid.org/0009-0005-4791-1279)
- V. Marc
- Kris Hage (ORCID: https://orcid.org/0000-0002-3273-3933)
- Lydia Fanny
- Vignesh Babu K
- Newsum Astrid
- Arends Joop
- van Eeden Arne
Institutions
- Burnet Institute (AU)
- Erasmus MC (NL)
- Maastricht University (NL)
- OLVG (NL)
- Amsterdam Neuroscience (NL)
- Kliniek ViaSana (NL)
- Department of Health (TW)
- Vincent Van Gogh Voor Geestelijke Gezondheidszorg (NL)
- Stichting HIV Monitoring (NL)
- GGD Amsterdam (NL)
- Amsterdam University Medical Centers (NL)
- Institute of Infection and Immunity (CA)
- Amsterdam University of Applied Sciences (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1097/qai.0000000000003550
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Gilead Sciences
- ViiV Healthcare
- ZonMw
- Janssen Pharmaceuticals
- Cilag